Biohaven Pharmaceutical Holding Co Ltd. (BHVN) stock is experiencing a significant pre-market surge on Monday, with shares climbing 5.18% ahead of the regular trading session. This notable uptick has caught the attention of investors and market analysts alike.

The catalyst behind this pre-market rally appears to be the recent announcement that Biohaven's Chief Executive Officer, Vlad Coric, has acquired additional common shares of the company. This move by the CEO is often interpreted as a strong vote of confidence in the company's future prospects and potential for growth.

Investors are likely viewing Coric's share acquisition as a positive signal, suggesting that the company's leadership believes the stock may be undervalued or that there could be promising developments on the horizon. While the exact number of shares acquired has not been disclosed in the initial report, the market's reaction indicates that this insider buying has resonated well with shareholders and potential investors, driving up demand for Biohaven's stock in early trading.